2223 GMT - Pathology services provider Healius's target of a high-single-digit Ebit margin by FY 2027 looks ambitious to Jefferies. Healius expects to reach this goal through a mix of revenue and cost initiatives. However, analyst David Stanton forecasts Healius achieving a 4.4% margin in FY 2028. "Growth in Ebit margin is not expected to be linear in the timeframe--we believe it is likely to be back-ended," Jefferies says. "We estimate that low-end to high-end targets imply FY 2028 Pathology Ebit margins of 7.0% to 8.6%." (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
March 27, 2025 18:23 ET (22:23 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。